Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to $586000.0.

  • Fulcrum Therapeutics' Amortizatization of Intangibles fell 4913.19% to $586000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 2638.74%. This contributed to the annual value of $4.4 million for FY2024, which is 2669.0% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Amortizatization of Intangibles of $586000.0 as of Q3 2025, which was down 4913.19% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Amortizatization of Intangibles registered a high of $1.7 million during Q2 2023, and its lowest value of -$386000.0 during Q4 2021.
  • For the 5-year period, Fulcrum Therapeutics' Amortizatization of Intangibles averaged around $638315.8, with its median value being $899000.0 (2025).
  • In the last 5 years, Fulcrum Therapeutics' Amortizatization of Intangibles plummeted by 100285.71% in 2021 and then skyrocketed by 151517.86% in 2023.
  • Fulcrum Therapeutics' Amortizatization of Intangibles (Quarter) stood at -$386000.0 in 2021, then skyrocketed by 255.7% to $601000.0 in 2022, then skyrocketed by 120.97% to $1.3 million in 2023, then decreased by 28.84% to $945000.0 in 2024, then crashed by 37.99% to $586000.0 in 2025.
  • Its last three reported values are $586000.0 in Q3 2025, $1.1 million for Q2 2025, and $899000.0 during Q1 2025.